<SEC-DOCUMENT>0000950170-21-001500.txt : 20210816
<SEC-HEADER>0000950170-21-001500.hdr.sgml : 20210816
<ACCEPTANCE-DATETIME>20210816164556
ACCESSION NUMBER:		0000950170-21-001500
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		13
CONFORMED PERIOD OF REPORT:	20210814
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20210816
DATE AS OF CHANGE:		20210816

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Viracta Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001061027
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				943295878
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-51531
		FILM NUMBER:		211179212

	BUSINESS ADDRESS:	
		STREET 1:		2533 S COAST HWY 101
		STREET 2:		SUITE 210
		CITY:			CARDIFF
		STATE:			CA
		ZIP:			92007
		BUSINESS PHONE:		858-400-8470

	MAIL ADDRESS:	
		STREET 1:		2533 S COAST HWY 101
		STREET 2:		SUITE 210
		CITY:			CARDIFF
		STATE:			CA
		ZIP:			92007

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	MOSAIC PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19980709

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SUNESIS PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19980501
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>virx-20210814.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2021-08-16T16:22:00.2621+00:00 -->
<!-- Copyright (c) 2021 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:virx="http://viracta.com/20210814">
 <head>
  <title>8-K</title>
  <meta http-equiv="Content-Type" content="text/html" />
 </head>
 <body>
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_83161532-5cef-4bc9-876c-f6b09ae879f5" name="dei:AmendmentFlag" contextRef="C_9b1044e9-7ffa-4cb5-bd5a-bcfe3efdd84f">false</ix:nonNumeric><ix:nonNumeric id="F_ecba88a7-e113-43e9-b297-fe7aa313fb8d" name="dei:EntityCentralIndexKey" contextRef="C_9b1044e9-7ffa-4cb5-bd5a-bcfe3efdd84f">0001061027</ix:nonNumeric><ix:nonNumeric id="F_c0b6bde1-654b-4f80-9110-370dd5bdfa0c" name="dei:EntityRegistrantName" contextRef="C_9b1044e9-7ffa-4cb5-bd5a-bcfe3efdd84f">Viracta Therapeutics, Inc.</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="virx-20210814.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="C_9b1044e9-7ffa-4cb5-bd5a-bcfe3efdd84f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001061027</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-14</xbrli:startDate><xbrli:endDate>2021-08-14</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div>
  <p style="border-top:2.250pt double rgba(0,0,0,1);text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:0.1pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:5.75pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:18.0pt;font-family:Times New Roman;">UNITED STATES<br />SECURITIES AND EXCHANGE COMMISSION<br /></span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">WASHINGTON, D.C. 20549</span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:0.2pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid rgba(0,0,0,1);margin-right:40.0%;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:10.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:18.0pt;font-family:Times New Roman;">FORM </span><span style="font-size:18.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_dd692225-640c-4e42-a810-e632338a9aa1" contextRef="C_9b1044e9-7ffa-4cb5-bd5a-bcfe3efdd84f" name="dei:DocumentType"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:18.0pt;font-family:Times New Roman;">8-K</span></ix:nonNumeric></span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:0.2pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid rgba(0,0,0,1);margin-right:40.0%;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">CURRENT REPORT</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:6.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:100.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.02986111111111111in;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Date of Report (Date of earliest event reported): </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b99c3ec9-7bcf-4d9c-93b5-6479f972968c" contextRef="C_9b1044e9-7ffa-4cb5-bd5a-bcfe3efdd84f" name="dei:DocumentPeriodEndDate" format="ixt:datemonthdayyearen"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">August 14, 2021</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="margin-left:40.0%;text-indent:0.0%;font-size:10.0pt;margin-top:5.0pt;line-height:0.05pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid rgba(0,0,0,1);margin-right:40.0%;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:0.05pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:5.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:24.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_c0b6bde1-654b-4f80-9110-370dd5bdfa0c;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:24.0pt;font-family:Times New Roman;">VIRACTA THERAPEUTICS, INC.</span></span></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">(Exact name of Registrant as Specified in Its Charter)</span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:0.05pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid rgba(0,0,0,1);margin-right:40.0%;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:0.05pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:20.0%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:20.0%;"></td>
    <td style="width:18.0%;"></td>
    <td style="width:41.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="3" style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_bd32e790-5d31-4404-92bd-25d7393696ca" contextRef="C_9b1044e9-7ffa-4cb5-bd5a-bcfe3efdd84f" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Delaware</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2ea3d5e5-7507-48e5-901a-d7dee4de0d4a" contextRef="C_9b1044e9-7ffa-4cb5-bd5a-bcfe3efdd84f" name="dei:EntityFileNumber"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">000-51531</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e532ebe6-57a3-4a26-9b07-a60280a08320" contextRef="C_9b1044e9-7ffa-4cb5-bd5a-bcfe3efdd84f" name="dei:EntityTaxIdentificationNumber"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">94-3295878</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td colspan="3" style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">(State or Other Jurisdiction<br />of Incorporation)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">(Commission File Number)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">(IRS Employer<br />Identification No.)</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="3" style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c7783b33-3694-44fc-a201-d605f56008f3" contextRef="C_9b1044e9-7ffa-4cb5-bd5a-bcfe3efdd84f" name="dei:EntityAddressAddressLine1"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2533 S. Coast Hwy. 101, Suite 210</span></ix:nonNumeric></span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="3" style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_bd4f3937-df4e-4ac1-a61d-b3d12fa85e41" contextRef="C_9b1044e9-7ffa-4cb5-bd5a-bcfe3efdd84f" name="dei:EntityAddressCityOrTown"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Cardiff</span></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">, </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5e070023-5b20-4e50-a44a-5717e158e7bf" contextRef="C_9b1044e9-7ffa-4cb5-bd5a-bcfe3efdd84f" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">California</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4d183478-3813-4e44-9033-b3abb4b3399c" contextRef="C_9b1044e9-7ffa-4cb5-bd5a-bcfe3efdd84f" name="dei:EntityAddressPostalZipCode"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">92007</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td colspan="3" style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">(Address of Principal Executive Offices)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">(Zip Code)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:0.05pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:100.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.125in;word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.02986111111111111in;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Registrant&#x2019;s Telephone Number, Including Area Code:</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d22267b1-db48-4d29-bb02-737ecdad4768" contextRef="C_9b1044e9-7ffa-4cb5-bd5a-bcfe3efdd84f" name="dei:CityAreaCode"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">(858)</span></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_40ca0034-52d4-4892-8000-a719b2a9bfce" contextRef="C_9b1044e9-7ffa-4cb5-bd5a-bcfe3efdd84f" name="dei:LocalPhoneNumber"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">400-8470</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:0.05pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:100.0%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.125in;word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">(Former Name or Former Address, if Changed Since Last Report)</span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;font-size:10.0pt;margin-top:9.35pt;line-height:0.05pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid rgba(0,0,0,1);margin-right:40.0%;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.35pt;line-height:1.3;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:9.0pt;line-height:1.3;margin-bottom:0.0pt;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7be732fb-9fa0-4115-a0c9-10532619e0c0" contextRef="C_9b1044e9-7ffa-4cb5-bd5a-bcfe3efdd84f" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox"><span style="font-size:10.0pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></div>
  <div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:6.0pt;line-height:1.3;margin-bottom:0.0pt;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_46d4835d-e3f1-48a5-a582-8af23c790564" contextRef="C_9b1044e9-7ffa-4cb5-bd5a-bcfe3efdd84f" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox"><span style="font-size:10.0pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></div>
  <div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:6.0pt;line-height:1.3;margin-bottom:0.0pt;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7b3135e4-a33f-415b-b302-b73a3c169bad" contextRef="C_9b1044e9-7ffa-4cb5-bd5a-bcfe3efdd84f" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox"><span style="font-size:10.0pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></div>
  <div style="text-indent:-24.5pt;padding-left:24.5pt;margin-top:6.0pt;line-height:1.3;margin-bottom:0.0pt;text-align:left;"><span style="margin-right:1em;margin-right:1em;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a7ae6a74-a4a7-41a5-bd64-6bc7aaa501d8" contextRef="C_9b1044e9-7ffa-4cb5-bd5a-bcfe3efdd84f" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox"><span style="font-size:10.0pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:9.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Securities registered pursuant to Section 12(b) of the Act:</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:38.0%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:15.0%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:45.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;border-bottom:1px solid;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"><br />Title of each class</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;border-bottom:0.011pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;border-bottom:1px solid;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Trading<br />Symbol(s)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;border-bottom:0.011pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;border-bottom:1px solid;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"><br />Name of each exchange on which registered</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_aa0f4845-1181-4655-a9ba-ce2b0fe6d5a9" contextRef="C_9b1044e9-7ffa-4cb5-bd5a-bcfe3efdd84f" name="dei:Security12bTitle"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Common Stock,  par value $0.0001 per share</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_20c4eb3b-424b-4aab-923b-60e63a31250d" contextRef="C_9b1044e9-7ffa-4cb5-bd5a-bcfe3efdd84f" name="dei:TradingSymbol"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">VIRX</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_deeac516-4820-4a51-b681-ac1c8e269259" contextRef="C_9b1044e9-7ffa-4cb5-bd5a-bcfe3efdd84f" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The NASDAQ Stock Market LLC</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;&#x202f;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;&#x202f;240.12b-2 of this chapter).</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Emerging growth company </span><span style="font-size:10.0pt;"><ix:nonNumeric id="F_03cb8e06-df2f-4fe2-9bab-a335fdf68347" contextRef="C_9b1044e9-7ffa-4cb5-bd5a-bcfe3efdd84f" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox"><span style="font-size:10.0pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:9.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="font-size:10.0pt;font-family:Times New Roman;">&#9744;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:0.1pt;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:2.250pt double rgba(0,0,0,1);text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">August 14, 2021, the Board of Directors (the &#x201c;Board&#x201d;) of Viracta Therapeutics, Inc. (the &#x201c;Company&#x201d;) increased the size of the Board to eleven (11) and appointed Flavia Borellini, Ph.D., and Jane F. Barlow, M.D., MPH, MBA to the Board to fill the vacancies resulting from such increase, in each case effective August 14, 2021. Dr. Barlow will serve as a Class II director and Dr. Borellini will serve as a Class III director.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Flavia Borellini, Ph.D., 61, has more than 25 years of executive management experience in the pharmaceutical and biotechnology industry, with a particular focus on global development of targeted oncology drugs, from preclinical to commercial stage. She is the former Chief Executive Officer for Acerta Pharma, where she oversaw the successful development and approval of Calquence&#174; (acalabrutinib), a selective Bruton's tyrosine kinase (BTK) inhibitor, for the treatment of mantle cell lymphoma and chronic lymphocytic leukemia (CLL). During her career, Dr. Borellini has also held key senior level positions within AstraZeneca, most recently Global Franchise Head, Hematology, with responsibility for the hematology portfolio in the company's oncology business unit. While at AstraZeneca, she led the global development, approval, and commercialization of Tagrisso&#174; (osimertinib), a first-in-class epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor for the treatment of non-small cell lung cancer (NSCLC) caused by the T790M mutation. Prior to her tenure with AstraZeneca, Dr. Borellini spent nearly seven years at Genentech, a member of the Roche Group. During this time, she led the global development, approval and launch of Zelboraf&#174; (vemurafenib), a first-in-class BRAF inhibitor for the treatment of melanoma caused by the V600E BRAF mutation. Dr. Borellini also served as the program leader for Herceptin&#174; (trastuzumab), a targeted treatment for HER2 receptor positive cancers, including breast cancer, and Tarceva&#174; (erlotinib), an EGFR tyrosine kinase inhibitor for the treatment of NSCLC and pancreatic cancer. Dr. Borellini also serves on the Board of Directors of Kartos Therapeutics, Cantargia AP, and Revolution Medicines.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Jane F. Barlow, M.D., MPH, MBA, 61, is currently the Chief Executive Officer of Jane Barlow &amp; Associates, LLC and a Board Director for ContraFect Corporation. She is Executive Vice President and Chief Clinical Officer at Real Endpoints, a market access consultancy, Senior Advisor to MIT's Center for Biomedical Innovation and serves on the biotech advisory board of Pictet Asset Management. Prior to her current roles, she was Associate Chief Medical Officer at CVS Health and Chief Medical Officer of CVS Health Government Services where she successfully implemented industry-leading clinical strategies supporting drug purchasing, distribution, and utilization management. Formerly, she served as Vice President of Clinical Innovation at Medco Health Solutions, leading the adoption of cutting-edge therapeutic programs through all aspects of pharmacy. Dr. Barlow has extensive experience in steering pharmaceutical development and commercialization by strategically weighing the value and economic impact that drug candidates bring to the healthcare ecosystem at large. Dr. Barlow previously served on the boards of Momenta Pharmaceuticals, Inc. (prior to and during its sale to Johnson and Johnson), TherapeuticsMD Inc., and SilverScript Insurance Company. Dr. Barlow received her medical degree from Creighton University School of Medicine and subsequently completed her residency in occupational and environmental medicine at The Johns Hopkins University, where she also earned her MPH She is a distinguished graduate of the United States Air Force School of Aerospace Medicine and served as Chief of Flight Medicine at the Beale and Maxwell Air Force Bases. Additionally, she holds an MBA from the University of Alabama. She is board-certified in occupational medicine and a fellow of the American College of Occupational and Environmental Medicine and the American College of Preventive Medicine. She is a diplomat of the American College of Physician Executives and a member of the American Medical Association.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Each of Dr. Borellini and Dr. Barlow will be compensated in accordance with the Company&#x2019;s amended and restated outside director compensation policy, which has been filed as Exhibit 10.12 to the Company&#x2019;s Quarterly Report on Form 10-Q filed with the SEC on May 13, 2021. In addition, each of Dr. Borellini and Dr. Barlow entered into the Company&#x2019;s standard form of indemnification agreement, a copy of which has been filed as Exhibit 10.5 to the Company&#x2019;s Registration Statement on Form S-1 (File No. 333-121646) filed with the SEC on December 23, 2004.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">There is no arrangement or understanding between either Dr. Borellini or Dr. Barlow and any other persons pursuant to which either Dr. Borellini or Dr. Barlow was elected as a director. In addition, neither Dr. Borellini nor Dr. Barlow is a party to any transaction, or series of transactions, required to be disclosed pursuant to Item 404(a) of Regulation S-K. There are no family relationships between either of Dr. Borellini or Dr. Barlow and any of the Company&#x2019;s directors or executive officers. The Board has determined that Dr. Borellini and Dr. Barlow meet the applicable independence requirements of The Nasdaq Stock Market LLC.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 7.01 Regulation FD Disclosure.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On August 16, 2021, the Company issued a press release announcing the appointments of Dr. Borellini and Dr. Barlow to the Board. A copy of the press release is furnished herewith as Exhibit 99.1.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The information set forth under this Item&#160;7.01, including Exhibit 99.1, shall not be deemed &#x201c;filed&#x201d; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, (the &#x201c;Exchange Act&#x201d;), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing, unless expressly incorporated by specific reference in such filing.</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 9.01 Financial Statements and Exhibits.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">&#160;(d) Exhibits</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:6.176%;"></td>
    <td style="width:4.843%;"></td>
    <td style="width:88.981%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Exhibit</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:1.0pt;border-bottom:1.000pt solid rgba(0,0,0,1);text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Number</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#160;&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1.000pt solid rgba(0,0,0,1);text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Description</span></p></td>
   </tr>
   <tr style="height:4.3pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">99.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><a href="virx-20210814ex99_1.htm"><span style="color:rgba(0,0,255,1);font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Press Release, dated August 16, 2021</span></a></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">104</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:9.35pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">SIGNATURES</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:9.35pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:6.0%;"></td>
    <td style="width:44.0%;"></td>
    <td style="width:4.0%;"></td>
    <td style="width:46.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:4.3pt;line-height:1.3;font-family:Times New Roman;margin-bottom:4.3pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Viracta Therapeutics, Inc.</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:4.3pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Date:</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:4.3pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">August 16, 2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:4.3pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">By:</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;border-bottom:1px solid;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:4.3pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ Daniel Chevallard</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.7pt;line-height:1.3;font-family:Times New Roman;margin-bottom:9.35pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Daniel Chevallard<br />Chief Operating Officer and Chief Financial Officer</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <hr style="page-break-after:always;" />
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>virx-20210814ex99_1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html>
 <head>
  <title>EX-99.1</title>
 </head>
 <body>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="font-size:12.0pt;font-family:Calibri;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Calibri;">Exhibit 99.1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Calibri;">Viracta Therapeutics Announces the Appointment of Flavia Borellini, Ph.D., and Jane F. Barlow, M.D., MPH, MBA, to its Board of Directors</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="font-size:12.0pt;font-family:Calibri;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Calibri;font-style:italic;">PR Newswire, San Diego, August 16, 2021 &#x2013; </font><font><font style="font-weight:normal;font-size:12.0pt;font-family:Calibri;">Viracta</font></font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Calibri;"> Therapeutics, Inc.  (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced the appointments of Flavia Borellini, Ph.D., and Jane F. Barlow, M.D., MPH, MBA, as independent members to Viracta&#x2019;s Board of Directors.</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Calibri;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="font-size:12.0pt;font-family:Calibri;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Calibri;">&#x201c;We are very pleased to welcome both Dr. Borellini and Dr. Barlow, two accomplished industry leaders with proven track records to the Viracta Board,&#x201d; said Roger J. Pomerantz, M.D., F.A.C.P., Chairman of the Board of Directors of Viracta. &#x201c;Their collective experience in corporate strategy, oncology drug development and navigating the regulatory landscapes, in addition to their deep commercial and pricing experience, will be invaluable as we position Viracta for long-term success in new oncology modalities. We look forward to their guidance and contributions to our future initiatives.&#x201d;</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Calibri;">  </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="font-size:12.0pt;font-family:Calibri;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Calibri;">Dr. Borellini commented, &#x201c;It is an honor to be a member of Viracta&#x2019;s Board. The Company has shown impressive clinical data and possesses a unique therapeutic approach with the potential to address unmet needs across multiple indications. I look forward to working with the fellow directors to provide valuable insights and counsel to the company&#x2019;s management team.&#x201d;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="font-size:12.0pt;font-family:Calibri;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Calibri;">Dr. Barlow added, &#x201c;This is an exciting time for Viracta, and I am thrilled to be joining the Board. The company&#x2019;s EBV-positive lymphoma program has advanced into an innovative pivotal trial, while its solid tumor program is poised to enter the clinic later this year. It also has a strong financial foundation and the backing of a premier group of institutional and healthcare-focused investors, which I believe positions the company well for sustained success.&#x201d;</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Calibri;">   </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="font-size:12.0pt;font-family:Calibri;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Calibri;">Appointee Bios</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="font-size:12.0pt;font-family:Calibri;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Calibri;font-style:italic;">Flavia Borellini, Ph.D.,</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Calibri;"> has more than 25 years of executive management experience in the pharmaceutical and biotechnology industry, with a particular focus on global development of targeted oncology drugs, from preclinical to commercial stage. She is the former Chief Executive Officer for Acerta Pharma, where she oversaw the successful development and approval of Calquence&#174;&#160;(acalabrutinib), a selective Bruton&#x2019;s tyrosine kinase (BTK) inhibitor, for the treatment of mantle cell lymphoma and chronic lymphocytic leukemia (CLL). During her career, Dr. Borellini has also held key senior level positions within AstraZeneca, most recently Global Franchise Head, Hematology, with responsibility for the hematology portfolio in the company&#x2019;s oncology business unit. While at AstraZeneca, she led the global development, approval, and commercialization of Tagrisso&#174;&#160;(osimertinib), a first-in-class epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor for the treatment of non-small cell lung cancer (NSCLC) caused by the T790M mutation.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Calibri;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Calibri;">Prior to her tenure with AstraZeneca, Dr. Borellini spent nearly seven years at Genentech, a member of the Roche Group. During this time, she led the global development, approval and launch of Zelboraf&#174;&#160;(vemurafenib), a first-in-class BRAF inhibitor for the treatment of melanoma caused by the V600E BRAF mutation. Dr. Borellini also served as the program leader for Herceptin&#174;&#160;(trastuzumab), a</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Calibri;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Calibri;">		Page | </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Calibri;">1</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Calibri;"> </font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Calibri;">targeted treatment for HER2 receptor positive cancers, including breast cancer, and Tarceva&#174;&#160;(erlotinib), an EGFR tyrosine kinase inhibitor for the treatment of NSCLC and pancreatic cancer.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="font-size:12.0pt;font-family:Calibri;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Calibri;">Dr. Borellini also serves on the Board of Directors of Kartos Therapeutics, Cantargia AP, and Revolution Medicines.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="font-size:12.0pt;font-family:Calibri;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Calibri;font-style:italic;">Jane F. Barlow, M.D., MPH, MBA,</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Calibri;"> is currently the Chief Executive Officer of Jane Barlow &amp; Associates, LLC and a Board Director for ContraFect Corporation.  She is Executive Vice President and Chief Clinical Officer at Real Endpoints, a market access consultancy, Senior Advisor to MIT&#x2019;s Center for Biomedical Innovation and serves on the biotech advisory board of Pictet Asset Management. Prior to her current roles, she was Associate Chief Medical Officer at CVS Health and Chief Medical Officer of CVS Health Government Services where she successfully implemented industry-leading clinical strategies supporting drug purchasing, distribution, and utilization management. Formerly, she served as Vice President of Clinical Innovation at Medco Health Solutions, leading the adoption of cutting-edge therapeutic programs through all aspects of pharmacy. Dr. Barlow has extensive experience in steering pharmaceutical development and commercialization by strategically weighing the value and economic impact that drug candidates bring to the healthcare ecosystem at large. Dr. Barlow previously served on the boards of Momenta Pharmaceuticals, Inc. (prior to and during its sale to Johnson and Johnson), TherapeuticsMD Inc., and SilverScript Insurance Company.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="font-size:12.0pt;font-family:Calibri;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Calibri;">Dr. Barlow received her medical degree from Creighton University School of Medicine and subsequently completed her residency in occupational and environmental medicine at The Johns Hopkins University, where she also earned her MPH She is a distinguished graduate of the United States Air Force School of Aerospace Medicine and served as Chief of Flight Medicine at the Beale and Maxwell Air Force Bases. Additionally, she holds an MBA from the University of Alabama. She is board-certified in occupational medicine and a fellow of the American College of Occupational and Environmental Medicine and the American College of Preventive Medicine. She is a diplomat of the American College of Physician Executives and a member of the American Medical Association.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="font-size:12.0pt;font-family:Calibri;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Calibri;">About Viracta Therapeutics, Inc.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="font-size:12.0pt;font-family:Calibri;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Calibri;">Viracta is a precision oncology company targeting virus-associated malignancies. Viracta's proprietary investigational drug, nanatinostat, is currently being evaluated in combination with the antiviral agent valganciclovir as an oral combination therapy in two Phase 2 clinical trials for EBV-positive lymphoma. Viracta is also pursuing application of its inducible synthetic lethality approach in other EBV-associated malignancies, such as nasopharyngeal carcinoma, gastric carcinoma, and other virus-related cancers.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="font-size:12.0pt;font-family:Calibri;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Calibri;">For additional information please visit&#160;</font><font><font style="font-weight:normal;font-size:12.0pt;font-family:Calibri;">www.viracta.com</font></font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Calibri;">.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Calibri;">		Page | </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Calibri;">2</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Calibri;"> </font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Calibri;">Forward-Looking Statements</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="font-size:12.0pt;font-family:Calibri;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Calibri;">This communication contains &#34;forward-looking&#34; statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, statements regarding:&#160; the significance of the Board of Director appointments and the expected contribution of the appointees; Viracta&#x2019;s clinical development plans; the potential of Viracta to address unmet needs across multiple indications; Viracta&#x2019;s ability to obtain and sustain success; and other statements that are not historical facts.&#160; Risks and uncertainties related to Viracta that may cause actual results to differ materially from those expressed or implied in any forward-looking statement include, but are not limited to: Viracta's ability to successfully enroll patients in and complete its ongoing and planned clinical trials; Viracta's plans to develop and commercialize its product candidates, including all oral combinations of nanatinostat and valganciclovir; the timing of initiation of Viracta's planned clinical trials; the timing of the availability of data from Viracta's clinical trials; previous preclinical and clinical results may not be predictive of future clinical results; the timing of any planned investigational new drug application or new drug application; Viracta's plans to research, develop and commercialize its current and future product candidates; the clinical utility, potential benefits and market acceptance of Viracta's product candidates; Viracta's ability to manufacture or supplying nanatinostat, valganciclovir and pembrolizumab for clinical testing; Viracta's ability to identify additional products or product candidates with significant commercial potential; developments and projections relating to Viracta's competitors and its industry; the impact of government laws and regulations; Viracta's ability to protect its intellectual property position; and Viracta's estimates regarding future expenses, capital requirements and need for additional financing in the future.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="font-size:12.0pt;font-family:Calibri;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Calibri;">These risks and uncertainties may be amplified by the COVID-19 pandemic, which has caused significant economic uncertainty. If any of these risks materialize or underlying assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. Additional risks and uncertainties that could cause actual outcomes and results to differ materially from those contemplated by the forward-looking statements are included under the caption &#34;Risk Factors&#34; and elsewhere in Viracta's reports and other documents that Viracta has filed, or will file, with the SEC from time to time and available at&#160;</font><font><font style="font-weight:normal;font-size:12.0pt;font-family:Calibri;">www.sec.gov</font></font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Calibri;">.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="font-size:12.0pt;font-family:Calibri;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Calibri;">The forward-looking statements included in this communication are made only as of the date hereof. Viracta assumes no obligation and does not intend to update these forward-looking statements, except as required by law or applicable regulation.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="font-size:11.0pt;font-family:Calibri;">&#160;</font></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:42.004%;"></td>
    <td style="width:57.996%;"></td>
   </tr>
   <tr style="height:12.25pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Calibri;">Investor Relations Contact:</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Calibri;"> </font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Calibri;">Viracta Contact:</font></p></td>
   </tr>
   <tr style="height:12.25pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Calibri;">Joyce Allaire</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Calibri;">Dan Chevallard</font></p></td>
   </tr>
   <tr style="height:15.1pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Calibri;">LifeSci Advisors</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Calibri;">Chief Operating Officer and Chief Financial Officer</font></p></td>
   </tr>
   <tr style="height:12.25pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font><font style="font-weight:normal;font-size:12.0pt;font-family:Calibri;">jallaire@lifesciadvisors.com</font></font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Calibri;"> </font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(5,99,193,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Calibri;">dchevallard@viracta.com</font></p></td>
   </tr>
   <tr style="height:11.5pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Calibri;">(212) 915-2569</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;padding-right:0.080in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Calibri;">(858) 771-4193</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:12.0pt;font-family:Calibri;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Calibri;"> SOURCE Viracta Therapeutics, Inc.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Calibri;">		Page | </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Calibri;">3</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Calibri;"> </font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>3
<FILENAME>virx-20210814_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2021-08-16T16:22:00.6074+00:00 -->
<!-- Copyright (c) 2021 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://viracta.com/20210814/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="virx-20210814.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://viracta.com/20210814/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="10010.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="10130.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="10020.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="10000.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="10090.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="10100.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="10120.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="10110.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="10040.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="10050.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="10060.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="10070.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="10030.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="10080.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="10140.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="10190.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="10180.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="10210.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="10340.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="10170.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="10220.0" priority="2" use="optional"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="10160.0" priority="2" use="optional"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>virx-20210814_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2021-08-16T16:22:00.5697+00:00 -->
<!-- Copyright (c) 2021 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications"/>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SolicitingMaterial_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_WrittenCommunications_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>virx-20210814.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2021-08-16T16:22:00.5012+00:00 -->
<!-- Copyright (c) 2021 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://viracta.com/20210814" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:virx="http://viracta.com/20210814" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd" namespace="http://fasb.org/us-gaap/2020-01-31"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd" namespace="http://xbrl.sec.gov/dei/2020-01-31"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="virx-20210814_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Labels link" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="virx-20210814_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation link" xlink:type="simple"/>
      <link:roleType roleURI="http://viracta.com/20210814/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>6
<FILENAME>virx-20210814_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="virx-20210814.xsd" xlink:type="simple"/>
    <context id="C_9b1044e9-7ffa-4cb5-bd5a-bcfe3efdd84f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001061027</identifier>
        </entity>
        <period>
            <startDate>2021-08-14</startDate>
            <endDate>2021-08-14</endDate>
        </period>
    </context>
    <dei:AmendmentFlag
      contextRef="C_9b1044e9-7ffa-4cb5-bd5a-bcfe3efdd84f"
      id="F_83161532-5cef-4bc9-876c-f6b09ae879f5">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="C_9b1044e9-7ffa-4cb5-bd5a-bcfe3efdd84f"
      id="F_ecba88a7-e113-43e9-b297-fe7aa313fb8d">0001061027</dei:EntityCentralIndexKey>
    <dei:EntityRegistrantName
      contextRef="C_9b1044e9-7ffa-4cb5-bd5a-bcfe3efdd84f"
      id="F_c0b6bde1-654b-4f80-9110-370dd5bdfa0c">Viracta Therapeutics, Inc.</dei:EntityRegistrantName>
    <dei:DocumentType
      contextRef="C_9b1044e9-7ffa-4cb5-bd5a-bcfe3efdd84f"
      id="F_dd692225-640c-4e42-a810-e632338a9aa1">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="C_9b1044e9-7ffa-4cb5-bd5a-bcfe3efdd84f"
      id="F_b99c3ec9-7bcf-4d9c-93b5-6479f972968c">2021-08-14</dei:DocumentPeriodEndDate>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_9b1044e9-7ffa-4cb5-bd5a-bcfe3efdd84f"
      id="F_bd32e790-5d31-4404-92bd-25d7393696ca">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="C_9b1044e9-7ffa-4cb5-bd5a-bcfe3efdd84f"
      id="F_2ea3d5e5-7507-48e5-901a-d7dee4de0d4a">000-51531</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_9b1044e9-7ffa-4cb5-bd5a-bcfe3efdd84f"
      id="F_e532ebe6-57a3-4a26-9b07-a60280a08320">94-3295878</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_9b1044e9-7ffa-4cb5-bd5a-bcfe3efdd84f"
      id="F_c7783b33-3694-44fc-a201-d605f56008f3">2533 S. Coast Hwy. 101, Suite 210</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="C_9b1044e9-7ffa-4cb5-bd5a-bcfe3efdd84f"
      id="F_bd4f3937-df4e-4ac1-a61d-b3d12fa85e41">Cardiff</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_9b1044e9-7ffa-4cb5-bd5a-bcfe3efdd84f"
      id="F_5e070023-5b20-4e50-a44a-5717e158e7bf">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_9b1044e9-7ffa-4cb5-bd5a-bcfe3efdd84f"
      id="F_4d183478-3813-4e44-9033-b3abb4b3399c">92007</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_9b1044e9-7ffa-4cb5-bd5a-bcfe3efdd84f"
      id="F_d22267b1-db48-4d29-bb02-737ecdad4768">(858)</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_9b1044e9-7ffa-4cb5-bd5a-bcfe3efdd84f"
      id="F_40ca0034-52d4-4892-8000-a719b2a9bfce">400-8470</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="C_9b1044e9-7ffa-4cb5-bd5a-bcfe3efdd84f"
      id="F_7be732fb-9fa0-4115-a0c9-10532619e0c0">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="C_9b1044e9-7ffa-4cb5-bd5a-bcfe3efdd84f"
      id="F_46d4835d-e3f1-48a5-a582-8af23c790564">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="C_9b1044e9-7ffa-4cb5-bd5a-bcfe3efdd84f"
      id="F_7b3135e4-a33f-415b-b302-b73a3c169bad">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="C_9b1044e9-7ffa-4cb5-bd5a-bcfe3efdd84f"
      id="F_a7ae6a74-a4a7-41a5-bd64-6bc7aaa501d8">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="C_9b1044e9-7ffa-4cb5-bd5a-bcfe3efdd84f"
      id="F_aa0f4845-1181-4655-a9ba-ce2b0fe6d5a9">Common Stock,  par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_9b1044e9-7ffa-4cb5-bd5a-bcfe3efdd84f"
      id="F_20c4eb3b-424b-4aab-923b-60e63a31250d">VIRX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_9b1044e9-7ffa-4cb5-bd5a-bcfe3efdd84f"
      id="F_deeac516-4820-4a51-b681-ac1c8e269259">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_9b1044e9-7ffa-4cb5-bd5a-bcfe3efdd84f"
      id="F_03cb8e06-df2f-4fe2-9bab-a335fdf68347">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139779845123368">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document And Entity Information<br></strong></div></th>
<th class="th"><div>Aug. 14, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Aug. 14,  2021<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Viracta Therapeutics, Inc.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001061027<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-51531<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">94-3295878<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2533 S. Coast Hwy. 101, Suite 210<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Cardiff<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92007<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(858)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">400-8470<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock,  par value $0.0001 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">VIRX<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>8
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
M.7\N?<^E[[GT/:'2MS<C?6?!TXM;WD9N6\3[KC':US0N*&-7<LW(QU2ODRG8
M.9_ [/UH/I[Q[?K9)(2OFEDM(Q:02X&S022X_(O*\"K$">AD6R4)RU3393>*
M$IY"&V[I4_5*E=?EK[DHN#Q;Y.FOH70^+,_Y/%_GM,T+,T.W<DOJMI2^M28X
M2O2QS'!.'LL,.V<\DAVV=Z =-?OV77;D(Z4P4Y=#N!I"O@-MNIW<.CB>F)&Y
M"M-2D&_#^>G%>!KB.=D$N7V85VWGV-'1^^?!4;"C[SR6'<>(\J(A[J&&F,_#
M0X=Y>U^89Y7&4#04;6RL)"Q&MV"XU_$L%.!D8"V@!X.O40+R4E5@,5O& RN0
MHGQ,C$7H<.>77%_CT9+CVZ9EM6ZO*7<9;2)2.<)IF!-GJ\K>9;'!51W/55OR
ML+YJ/;053L_^6:W(GPP13A8+$DACE!>F2J+S&5.^YRM)Q%4XOT4SMA*7&+SC
MYL=Q3E.X$G:V#P(RN;LYJ7IE,6>F\M\M# DL6XA9$N)-7>W5YYN<KGHB=OJ7
M=\%@\OUPR4</Y3OG7_1=0ZY^]MWC^FZ3.TA,G'G%$0%T10(CE1P&%A<RY%#N
MDI &$P'-E,E$\ *"9*8<@)CZ"[WR#+DI%<ZM/CE_12R#ADY>TB42%(JP# 4A
M%W+C[^^3:G>,U_HL@6V$5#)DU1?*0XG!/3-R0]A4)?.NVB8+A=OB5,V[&KXF
M8$O#>FZ=+2?_VU[4/;07/4;SHYG@'K.'<YMZN,)%K/]8UA[Y,M\Y<-LZW@->
MYA,L0Z1^P7V*BH 1JV*^NJ]/^26<.[1[\8$@F_S6VZ3VW> ,?-2K6J5D*Q$_
M2P=\'Y(&8XQ;]#1?CQ1BK::QK<;:,0QY@%CS#*%F.-^'19H:,]6+K#F-"F]!
MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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MD1:7$6>0<G8"/ ^E-*\#>RPM_ZLP^0]02P,$%     @ M(404Y^@&_"Q @
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M\SR. !9GD*88 J<11S &P %#TG1X#SY['R73>RHY_U=3_ 102P,$%     @
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M-4H2U\7!ZQ^4ZD2HN7/08&<B+EA0BJN$7/D=<.I[.T!*1D.QD8E>I6.5Z*U
M.EK >MKBRAE#VQH%.JB]XY8:8P*IL0,@9^O1=#%-)IXPC,^[V?S!9@K(RDT*
M$3FQ!'_'G2/)W55D(TADIJ]X(;+U[/M!3EN#OI'-X_T,:3?D@6)8YL_X>\87
M_QO.\1'"[K\_L;S63AI_YHOA/UY_ 5!+ 0(4 Q0    ( +2%$%,'04UB@0
M +$    0              "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#
M%     @ M(404PQ[[6SO    *P(  !$              ( !KP   &1O8U!R
M;W!S+V-O<F4N>&UL4$L! A0#%     @ M(404YE<G",0!@  G"<  !,
M         ( !S0$  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    " "T
MA1!3X#PB/$X$  !A$   &               @($."   >&PO=V]R:W-H965T
M<R]S:&5E=#$N>&UL4$L! A0#%     @ M(404Y^@&_"Q @  X@P   T
M         ( !D@P  'AL+W-T>6QE<RYX;6Q02P$"% ,4    " "TA1!3EXJ[
M',     3 @  "P              @ %N#P  7W)E;',O+G)E;'-02P$"% ,4
M    " "TA1!3.JJBYT !   \ @  #P              @ %7$   >&PO=V]R
M:V)O;VLN>&UL4$L! A0#%     @ M(404R0>FZ*M    ^ $  !H
M     ( !Q!$  'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%
M  @ M(404V60>9(9 0  SP,  !,              ( !J1(  %M#;VYT96YT
A7U1Y<&5S72YX;6Q02P4&      D "0 ^ @  \Q,

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>96</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="virx-20210814.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://viracta.com/20210814/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="virx-20210814.htm">virx-20210814.htm</File>
    <File>virx-20210814.xsd</File>
    <File>virx-20210814_lab.xml</File>
    <File>virx-20210814_pre.xml</File>
    <File>virx-20210814ex99_1.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "virx-20210814.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "definitionLink": {
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml",
      "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "virx-20210814.htm"
     ]
    },
    "labelLink": {
     "local": [
      "virx-20210814_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "virx-20210814_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "virx-20210814.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd",
      "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 23,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2020-01-31": 3,
    "total": 3
   },
   "keyCustom": 0,
   "keyStandard": 96,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "virx",
   "nsuri": "http://viracta.com/20210814",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "virx-20210814.htm",
      "contextRef": "C_9b1044e9-7ffa-4cb5-bd5a-bcfe3efdd84f",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document And Entity Information",
     "role": "http://viracta.com/20210814/taxonomy/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document And Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "virx-20210814.htm",
      "contextRef": "C_9b1044e9-7ffa-4cb5-bd5a-bcfe3efdd84f",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://viracta.com/20210814/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://viracta.com/20210814/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://viracta.com/20210814/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://viracta.com/20210814/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://viracta.com/20210814/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://viracta.com/20210814/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://viracta.com/20210814/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://viracta.com/20210814/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://viracta.com/20210814/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://viracta.com/20210814/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://viracta.com/20210814/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://viracta.com/20210814/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://viracta.com/20210814/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://viracta.com/20210814/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://viracta.com/20210814/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://viracta.com/20210814/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://viracta.com/20210814/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://viracta.com/20210814/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://viracta.com/20210814/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://viracta.com/20210814/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://viracta.com/20210814/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://viracta.com/20210814/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0000950170-21-001500-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000950170-21-001500-xbrl.zip
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M_I-SQ/^1BAR("5-$BZC,.\P6EUJ\. X]"I21 WT^E?O=EFWOWV>KK8K@2@0
M&F<Q0)*9XRXN"C":;-,IF67NF L\W6+;:)'NR04Q+;T!!:?:H#JJ[&EDW'S3
M9&PWF=VV'*9Q*S# Z:! QDX;/ \:F);?<G6G:3^5C/N@QWR8CVAP"D(4)&GX
M,]'P=/1D5 Y_D8 -FVJ&.4/#M?-9)A0,"E^5W!!Q719;AN5P6Z.6%8 L=CS-
MLW13\UH6M7RCZ7J4/96(SU..<AA/CI0'9J&.3[\% ?C0/Q$Q Q8T?P8-]TIF
MPV::N>WM+$?:JNR&N&>)F[8H;](6$+=-6T#<% FU:6M-SV]12AW=8$\.Y,T1
M=R_+"IYN2'Q)$K>X9N/9X<N0>%EVD<1?Y\PR]T4<^N7TXM1*4RX/3\%I2FX[
MR4P*D-(% HQVWD#@S+K_*(3[CUPPG&=HQ)YO9-U.3*L'/XSD1@4^WE[ [R6X
M1&T]N\3#VM7I:/Z0^"'-LM=<SI\/5^F&40]7F8ZS6_T?/^^LT^2]^?RW#=/<
M,SV7*47,ED=/CT?0QO;KIAAM.&;#,>O,,8I5SLK#T*26X94-"Q;8]5# FZF9
M]N0='9N<LY=)#Z94#^RV[6B&T38TN^DX&G4]JOG<]/2 -\$)=)\<SE.&^]@P
M/6F7K&8]!IPP(,1^'OO?=PD!$YU<T;#@Y+^AMJX;),%[-H;K>5C3&I'>NQ#E
M/R5KF[IO<\_R--O$\T4I]337A,>FSIL6M0S3T9\<Y"P-)V4RK82O?^]=_+'A
MV W'OD>.91P,*<=H:G8;-^51Q]"\)JAEZAM^FYM-UW2>31E7$4=U;==\M!9M
MN4?MPWL<4U\..3D[[!\=_ETI;')*T^\\)U^_=E\E"["\0^&%F?)E<-F+&(:>
M.?'&Q)=)*0#:=[#(N3SB:RYC1&0$ .* U $N. ([7^=#C& GF$5",\)X %B0
MYQJKE7/=N>5VB.FE$!;91NG1VI<IU&:P+U?1JTK0'9!=@B<C8U*6"H>;GF8N
M>>/$0N,8(I_6GVF^\7I9+FMRM\KJ2.[X#O)9*O'Y#EFH6[[7YGI38X$9:';
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M7_$P3BKMD0,6.0J1./)58RPM!B"T)*\GP%HX'NP6A(/,-4NE\0D6YX W2!_
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M2_+TT=\CL>\7B9R_TDSCT94 9T3B*%1@R#9S'*,:,?D2)V!O9#-@S#IATG(
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M@)-80^S(D*]_O[;!- 1#LJ1 KX:!X]?/ 9OXO+A7G]<S#Y:(^9B2ZX;5;#4
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M0^?VRHZ7YQ3L\<" G-(S4Z>]W/9B^7'):"'G/*HJ>(X_\F(]NH8./$AK1SS
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M^X_"OU&S_XC_=9O_!U!+ 0(4 Q0    ( +2%$%,D)5:I4!P  &7;   1
M          "  0    !V:7)X+3(P,C$P.#$T+FAT;5!+ 0(4 Q0    ( +2%
M$%/"=[@1^ (  'D)   1              "  7\<  !V:7)X+3(P,C$P.#$T
M+GAS9%!+ 0(4 Q0    ( +2%$%-5QRI8FP4  (<R   5              "
M :8?  !V:7)X+3(P,C$P.#$T7VQA8BYX;6Q02P$"% ,4    " "TA1!3[%AK
M[H@$  !L)0  %0              @ %T)0  =FER>"TR,#(Q,#@Q-%]P<F4N
M>&UL4$L! A0#%     @ M(404R:N*L/5$@  Y&8  !<              ( !
M+RH  '9I<G@M,C R,3 X,31E>#DY7S$N:'1M4$L%!@     %  4 20$  #D]
$      $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
